董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Thomas Zindrick | 男 | President, Chief Executive Officer and Chairman | 67 | 427.71万美元 | 185.42 | 2026-01-02 |
| Mary Mirabelli | 女 | Director | 69 | 22.30万美元 | 13.99 | 2026-01-02 |
| John Thomas | 男 | Director | 68 | 22.65万美元 | 58.36 | 2026-01-02 |
| John Smither | 男 | Director | 72 | 22.40万美元 | 11.79 | 2026-01-02 |
| James L. Tyree | 男 | Lead Independent Director | 73 | 26.40万美元 | 19.85 | 2026-01-02 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Thomas Zindrick | 男 | President, Chief Executive Officer and Chairman | 67 | 427.71万美元 | 185.42 | 2026-01-02 |
| Tony Yu | 男 | Senior Vice President, Clinical Development | 55 | 未披露 | 未持股 | 2026-01-02 |
| Joseph Cappello | 男 | Chief Technical Officer | 69 | 144.21万美元 | 20.26 | 2026-01-02 |
| Ralph Smalling | 男 | Head of Regulatory | 70 | 未披露 | 未持股 | 2026-01-02 |
| Matthew Pulisic | 男 | Chief Financial Officer | 42 | 148.70万美元 | 8.59 | 2026-01-02 |
| Eric Groen | 男 | General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development | 55 | 未披露 | 未持股 | 2026-01-02 |
| Jason Litten | 男 | Chief Medical Officer | 52 | 未披露 | 未持股 | 2026-01-02 |
董事简历
中英对照 | 中文 | 英文- Thomas Zindrick
-
Thomas Zindrick自2014年5月起担任Genelux公司总裁、首席执行官和Genelux公司董事会成员，自2021年7月起担任Genelux公司主席。目前，他担任Aeromics，Inc的执行主席，该公司是一家临床阶段的制药公司，自2018年8月起开发用于治疗缺血性中风水肿的产品。2012年至2014年，Zindrick先生担任Amitech Therapeutic Solutions，Inc.的首席执行官。1993年至2009年，Zindrick先生在安进公司担任越来越重要的职务，包括2001年至2004年担任副总裁副总法律顾问，2008年至2009年再次担任该职务。2004年至2008年，Zindrick先生在安进公司担任首席合规官。在加入Amgen公司之前，Zindrick先生是陶氏化学公司的一名律师。Zindrick先生于2011年至2021年2月担任Amitech Therapeutic Solutions，Inc.的董事会成员，并于2014年11月至2020年3月担任DNX Biopharmaceuticals，Inc.的董事会成员。Zindrick先生在伊利诺伊大学法学院获得法学博士学位，在伊利诺斯州内珀维尔的北中央学院获得生物学学士学位。
Thomas Zindrick,has served as Genelux Corporation President, Chief Executive Officer and a member of Genelux Corporation Board since May 2014 and as Genelux Corporation Chair since July 2021. Currently, he serves as Executive Chair of Aeromics, Inc., a clinical-stage pharmaceutical company developing products for the treatment of edema in ischemic stroke, since August 2018. Mr. Zindrick served as Chief Executive Officer of Amitech Therapeutic Solutions, Inc., from March 2012 to May 2014. From 1993 to 2009, Mr. Zindrick was at Amgen Inc. ("Amgen"), a public commercial biotechnology company, where he held positions of increasing responsibility, including Vice President Associate General Counsel from 2001 to 2004 and again from 2008 to 2009. At Amgen, from 2004 to 2008, Mr. Zindrick served as Chief Compliance Officer. Prior to joining Amgen, Mr. Zindrick was an attorney at The Dow Chemical Company. Mr. Zindrick served on the board of directors of Amitech Therapeutic Solutions, Inc. from October 2011 to February 2021 and DNX Biopharmaceuticals, Inc. from November 2014 to March 2020. Mr. Zindrick received his J.D. from the University of Illinois College of Law and a B.A. in biology from North Central College in Naperville, Illinois. - Thomas Zindrick自2014年5月起担任Genelux公司总裁、首席执行官和Genelux公司董事会成员，自2021年7月起担任Genelux公司主席。目前，他担任Aeromics，Inc的执行主席，该公司是一家临床阶段的制药公司，自2018年8月起开发用于治疗缺血性中风水肿的产品。2012年至2014年，Zindrick先生担任Amitech Therapeutic Solutions，Inc.的首席执行官。1993年至2009年，Zindrick先生在安进公司担任越来越重要的职务，包括2001年至2004年担任副总裁副总法律顾问，2008年至2009年再次担任该职务。2004年至2008年，Zindrick先生在安进公司担任首席合规官。在加入Amgen公司之前，Zindrick先生是陶氏化学公司的一名律师。Zindrick先生于2011年至2021年2月担任Amitech Therapeutic Solutions，Inc.的董事会成员，并于2014年11月至2020年3月担任DNX Biopharmaceuticals，Inc.的董事会成员。Zindrick先生在伊利诺伊大学法学院获得法学博士学位，在伊利诺斯州内珀维尔的北中央学院获得生物学学士学位。
- Thomas Zindrick,has served as Genelux Corporation President, Chief Executive Officer and a member of Genelux Corporation Board since May 2014 and as Genelux Corporation Chair since July 2021. Currently, he serves as Executive Chair of Aeromics, Inc., a clinical-stage pharmaceutical company developing products for the treatment of edema in ischemic stroke, since August 2018. Mr. Zindrick served as Chief Executive Officer of Amitech Therapeutic Solutions, Inc., from March 2012 to May 2014. From 1993 to 2009, Mr. Zindrick was at Amgen Inc. ("Amgen"), a public commercial biotechnology company, where he held positions of increasing responsibility, including Vice President Associate General Counsel from 2001 to 2004 and again from 2008 to 2009. At Amgen, from 2004 to 2008, Mr. Zindrick served as Chief Compliance Officer. Prior to joining Amgen, Mr. Zindrick was an attorney at The Dow Chemical Company. Mr. Zindrick served on the board of directors of Amitech Therapeutic Solutions, Inc. from October 2011 to February 2021 and DNX Biopharmaceuticals, Inc. from November 2014 to March 2020. Mr. Zindrick received his J.D. from the University of Illinois College of Law and a B.A. in biology from North Central College in Naperville, Illinois.
- Mary Mirabelli
-
Mary Mirabelli，自2021年6月起担任Genelux公司董事会成员。Mirabelli女士自2018年4月起担任医疗保健财务管理协会高级副总裁。在此之前，米拉贝利女士于2014年6月至2017年4月担任惠普企业公司全球Healthcare Services副总裁。Mirabelli女士于2010年至2014年在美国医院公司担任高级主管。Mirabelli女士拥有伊利诺伊大学香槟分校职业治疗学士学位和西北大学凯洛格管理研究生院管理学硕士学位。
Mary Mirabelli,has served as a member of the Board since June 2021. Most recently, Ms. Mirabelli served as the Senior Vice President at the Healthcare Finance Management Association from April 2018 to November 2023. Previously, Ms. Mirabelli served as the Vice President of Global Healthcare Services at Hewlett Packard Enterprise Company from June 2014 to April 2018. Ms. Mirabelli served as a senior executive at Hospital Corporation of America from 2000 to 2014. Since January 2024, Ms. Mirabelli has served as a member on the board of directors of Health IT Leaders, a health information technology consulting firm. Ms. Mirabelli holds a B.S. in occupational therapy from University of Illinois at Urbana-Champaign and an M.B.A. in management from Northwestern University's Kellogg Graduate School of Management. - Mary Mirabelli，自2021年6月起担任Genelux公司董事会成员。Mirabelli女士自2018年4月起担任医疗保健财务管理协会高级副总裁。在此之前，米拉贝利女士于2014年6月至2017年4月担任惠普企业公司全球Healthcare Services副总裁。Mirabelli女士于2010年至2014年在美国医院公司担任高级主管。Mirabelli女士拥有伊利诺伊大学香槟分校职业治疗学士学位和西北大学凯洛格管理研究生院管理学硕士学位。
- Mary Mirabelli,has served as a member of the Board since June 2021. Most recently, Ms. Mirabelli served as the Senior Vice President at the Healthcare Finance Management Association from April 2018 to November 2023. Previously, Ms. Mirabelli served as the Vice President of Global Healthcare Services at Hewlett Packard Enterprise Company from June 2014 to April 2018. Ms. Mirabelli served as a senior executive at Hospital Corporation of America from 2000 to 2014. Since January 2024, Ms. Mirabelli has served as a member on the board of directors of Health IT Leaders, a health information technology consulting firm. Ms. Mirabelli holds a B.S. in occupational therapy from University of Illinois at Urbana-Champaign and an M.B.A. in management from Northwestern University's Kellogg Graduate School of Management.
- John Thomas
-
John Thomas，自2002年9月起担任Genelux公司董事会成员。Thomas博士于2002年至2004年担任Genelux公司首任首席财务官。托马斯博士自1988年以来一直担任拉塞拉大学商业和管理学院院长。Thomas博士自2004年1月起担任KSGN Good News Radio的董事会成员，自2009年1月起担任Loma Linda Broadcasting Network International的董事会成员，自2015年9月起担任ADRA国际的财务委员会成员。他曾于1992年至2018年担任家庭服务协会董事会成员。Thomas博士拥有拉塞拉大学金融学硕士学位和共生管理研究所市场营销硕士学位，克莱蒙特研究生大学国际政治经济学硕士学位和克莱蒙特研究生大学政治经济学博士学位。
John Thomas,has served as a member of the Board since September 2002. Dr. Thomas served as Genelux Corporation first Chief Financial Officer from 2002 to 2004. Dr. Thomas has been the Dean of the School of Business and Management at La Sierra University since 1999. Dr. Thomas has served on the boards of directors of ICON Business Bank, a financial institution, since June 2023, KSGN Good News Radio, a non-profit organization, since January 2004, Loma Linda Broadcasting Network International, a broadcasting network, since January 2009 and ADRA International, a humanitarian aid organization, as a member of the finance committee since September 2015. He previously served as a member of the board of directors of the Family Service Association, a non-profit public benefit health and human service agency, from 1992 to 2018. Dr. Thomas holds an M.B.A. in finance from Loma Linda University and an M.B.A. in marketing from Symbiosis Institute of Management Studies, an M.A. in international political economy from Claremont Graduate University and a Ph.D. in political economy from Claremont Graduate University. - John Thomas，自2002年9月起担任Genelux公司董事会成员。Thomas博士于2002年至2004年担任Genelux公司首任首席财务官。托马斯博士自1988年以来一直担任拉塞拉大学商业和管理学院院长。Thomas博士自2004年1月起担任KSGN Good News Radio的董事会成员，自2009年1月起担任Loma Linda Broadcasting Network International的董事会成员，自2015年9月起担任ADRA国际的财务委员会成员。他曾于1992年至2018年担任家庭服务协会董事会成员。Thomas博士拥有拉塞拉大学金融学硕士学位和共生管理研究所市场营销硕士学位，克莱蒙特研究生大学国际政治经济学硕士学位和克莱蒙特研究生大学政治经济学博士学位。
- John Thomas,has served as a member of the Board since September 2002. Dr. Thomas served as Genelux Corporation first Chief Financial Officer from 2002 to 2004. Dr. Thomas has been the Dean of the School of Business and Management at La Sierra University since 1999. Dr. Thomas has served on the boards of directors of ICON Business Bank, a financial institution, since June 2023, KSGN Good News Radio, a non-profit organization, since January 2004, Loma Linda Broadcasting Network International, a broadcasting network, since January 2009 and ADRA International, a humanitarian aid organization, as a member of the finance committee since September 2015. He previously served as a member of the board of directors of the Family Service Association, a non-profit public benefit health and human service agency, from 1992 to 2018. Dr. Thomas holds an M.B.A. in finance from Loma Linda University and an M.B.A. in marketing from Symbiosis Institute of Management Studies, an M.A. in international political economy from Claremont Graduate University and a Ph.D. in political economy from Claremont Graduate University.
- John Smither
-
John Smither，自2018年3月起担任Old eFFECTOR董事会成员，自2021年8月起担任董事会成员。Smither先生最近于2019年5月至2021年3月担任Arcutis生物治疗公司的首席财务官，负责所有财务方面的工作，包括领导公司成功的首次公开发行和两次后续融资。此前，Smither先生于2016年1月至2017年4月担任Sienna Biopharmaceutics的首席财务官，并于2018年4月至2019年3月再次担任首席财务官。2017年11月至2018年4月，他还担任吉利德公司Kite Pharma的临时首席财务官，并担任Unity Biotechnology的首席财务官。他还曾担任Kythera生物制药的首席财务官，负责从批准到上市的早期临床阶段的所有财务活动，领导私募融资，为公司在2012年10月成功进行首次公开发行做准备，并监督艾尔建以大约21亿美元收购该公司。在安进，他担任过多个财务职位，责任越来越大，包括负责安进在28个国家的欧洲业务的财务和行政副总裁，还担任过公司会计执行董事。2023年1月，Smither先生被任命为NewAmsterdam Pharma董事会成员，并担任其审计委员会主席。自2022年1月起，Smither先生担任Applied Molecular Transport Inc.董事会成员，并担任其审计委员会主席和薪酬委员会成员。此外，从2013年12月至2020年5月，Smither先生担任Achaogen, Inc.董事会成员、审计委员会主席和薪酬委员会成员。Smither先生的职业生涯始于安永，在那里他是审计合伙人，并持有注册会计师证书（非在职）。他以优异的成绩获得了加州州立大学洛杉矶分校会计学学士学位。
John Smither,served on Old eFFECTOR's board of directors from March 2018 and has served on the Board since August 2021. Mr. Smither most recently served as the chief financial officer of Arcutis Biotherapeutics, Inc. from May 2019 to March 2021 where he was responsible for all financial aspects including leading the company's successful initial public offering and two follow-on financings. Previously, Mr. Smither was the chief financial officer at Sienna Biopharmaceutics from January 2016 to April 2017, and again from April 2018 to March 2019. He also served as the interim chief financial officer at Kite Pharma, a Gilead Company from November 2017 through April 2018, and was the chief financial officer of Unity Biotechnology. He also served as chief financial officer at Kythera Biopharmaceuticals, where he was responsible for all financial activities during early clinical stage through approval and launch, led private fundraising rounds, prepared the company for its successful initial public offering in October 2012, and oversaw its acquisition by Allergan for approximately $2.1 billion. At Amgen, he held several financial positions of increasing responsibility, including vice president of finance and administration for Amgen's European operations in 28 countries, and also served as Executive Director, Corporate Accounting. In January 2023, Mr. Smither was appointed to the board of NewAmsterdam Pharma and is its chair of the audit committee, and since January 2022, Mr. Smither has served as member of the board of directors of Applied Molecular Transport Inc., and is its chair of the audit committee, and a member of the compensation committee. Additionally, from December 2013 to May 2020, Mr. Smither served as a member of the board of directors of Achaogen, Inc., and was its chair of the audit committee, and a member of the compensation committee. Mr. Smither began his career at Ernst & Young, where he was audit partner and held certification as a Certified Public Accountant (inactive). He holds a B.S. in accounting, with honors, from California State University at Los Angeles. - John Smither，自2018年3月起担任Old eFFECTOR董事会成员，自2021年8月起担任董事会成员。Smither先生最近于2019年5月至2021年3月担任Arcutis生物治疗公司的首席财务官，负责所有财务方面的工作，包括领导公司成功的首次公开发行和两次后续融资。此前，Smither先生于2016年1月至2017年4月担任Sienna Biopharmaceutics的首席财务官，并于2018年4月至2019年3月再次担任首席财务官。2017年11月至2018年4月，他还担任吉利德公司Kite Pharma的临时首席财务官，并担任Unity Biotechnology的首席财务官。他还曾担任Kythera生物制药的首席财务官，负责从批准到上市的早期临床阶段的所有财务活动，领导私募融资，为公司在2012年10月成功进行首次公开发行做准备，并监督艾尔建以大约21亿美元收购该公司。在安进，他担任过多个财务职位，责任越来越大，包括负责安进在28个国家的欧洲业务的财务和行政副总裁，还担任过公司会计执行董事。2023年1月，Smither先生被任命为NewAmsterdam Pharma董事会成员，并担任其审计委员会主席。自2022年1月起，Smither先生担任Applied Molecular Transport Inc.董事会成员，并担任其审计委员会主席和薪酬委员会成员。此外，从2013年12月至2020年5月，Smither先生担任Achaogen, Inc.董事会成员、审计委员会主席和薪酬委员会成员。Smither先生的职业生涯始于安永，在那里他是审计合伙人，并持有注册会计师证书（非在职）。他以优异的成绩获得了加州州立大学洛杉矶分校会计学学士学位。
- John Smither,served on Old eFFECTOR's board of directors from March 2018 and has served on the Board since August 2021. Mr. Smither most recently served as the chief financial officer of Arcutis Biotherapeutics, Inc. from May 2019 to March 2021 where he was responsible for all financial aspects including leading the company's successful initial public offering and two follow-on financings. Previously, Mr. Smither was the chief financial officer at Sienna Biopharmaceutics from January 2016 to April 2017, and again from April 2018 to March 2019. He also served as the interim chief financial officer at Kite Pharma, a Gilead Company from November 2017 through April 2018, and was the chief financial officer of Unity Biotechnology. He also served as chief financial officer at Kythera Biopharmaceuticals, where he was responsible for all financial activities during early clinical stage through approval and launch, led private fundraising rounds, prepared the company for its successful initial public offering in October 2012, and oversaw its acquisition by Allergan for approximately $2.1 billion. At Amgen, he held several financial positions of increasing responsibility, including vice president of finance and administration for Amgen's European operations in 28 countries, and also served as Executive Director, Corporate Accounting. In January 2023, Mr. Smither was appointed to the board of NewAmsterdam Pharma and is its chair of the audit committee, and since January 2022, Mr. Smither has served as member of the board of directors of Applied Molecular Transport Inc., and is its chair of the audit committee, and a member of the compensation committee. Additionally, from December 2013 to May 2020, Mr. Smither served as a member of the board of directors of Achaogen, Inc., and was its chair of the audit committee, and a member of the compensation committee. Mr. Smither began his career at Ernst & Young, where he was audit partner and held certification as a Certified Public Accountant (inactive). He holds a B.S. in accounting, with honors, from California State University at Los Angeles.
- James L. Tyree
-
James L. Tyree，自2012年5月起担任董事会成员，自2021年7月起担任Genelux Corporation首席独立董事。Tyree先生此前曾于2014年至2021年担任董事会主席。Tyree先生是Tyree & D'Angelo Partners的退休联合创始人和管理合伙人，该公司是一家成立于2014年的私募股权投资公司。在创立Tyree & D'Angelo Partners之前，Tyree先生于2012年担任Abbott Biotech Ventures（Abbott）的执行副总裁兼总裁，该公司是雅培的子公司。在担任该职位之前，Tyree先生曾在雅培担任多个行政职务，包括执行副总裁Global Pharmaceuticals、高级副总裁Global Nutrition、公司副总裁制药和营养产品集团业务发展以及部门副总裁兼总经理，1997年至2000年，日本。Tyree先生还自2012年6月起担任生物制药公司ChemoCentryx，Inc.的董事会成员，直到该公司于2022年出售给安进，当时担任首席独立董事。Tyree先生此前曾于2012年3月至2022年11月担任医疗器械公司SonarMed，Inc.（现为美敦力 PLC的子公司）的董事会成员。Tyree先生于2016年10月至2024年4月期间担任上市制药公司Assertio Holdings, Inc.的董事会成员和薪酬委员会主席。Tyree先生此前曾担任伊利诺伊州生物技术产业组织董事会主席、芝加哥大学布斯商学院顾问委员会成员，以及主持全球健康政策圆桌会议的芝加哥全球事务委员会成员。Tyree先生获得了心理学和法医学研究学士学位，并获得了印第安纳大学的工商管理硕士学位。
James L. Tyree,has served as a member of the Board since May 2012 and as Genelux Corporation Lead Independent Director since July 2021. Mr. Tyree previously served as Chairman of the Board from 2014 to 2021. Mr. Tyree is the retired co-founder and managing partner of Tyree & D'Angelo Partners, a private equity investment firm founded in 2014. Prior to founding Tyree & D'Angelo Partners, Mr. Tyree served as Executive Vice President and President of Abbott Biotech Ventures (Abbott), a subsidiary of Abbott Laboratories in 2012. Prior to that position, Mr. Tyree held numerous executive positions at Abbott, including Executive Vice President Global Pharmaceuticals, Senior Vice President Global Nutrition, Corporate Vice President Pharmaceutical and Nutritional Products Group Business Development and Divisional Vice President and General Manager, Japan from 1997 to 2000. Mr. Tyree also served as a member of the board of directors of ChemoCentryx, Inc., a biopharmaceutical company, since June 2012, until the company was sold to Amgen in 2022 and at that time was lead independent director. Mr. Tyree previously served as a member of the board of directors of SonarMed, Inc., a medical device company (now a subsidiary of Medtronic plc), from March 2012 to November 2022. Mr. Tyree served as a member of the board of directors and chair of the compensation committee of Assertio Holdings, Inc., a public pharmaceutical company, from October 2016 to April 2024. Mr. Tyree previously served as chairman of the board of directors of the Illinois Biotechnology Industry Organization, as a member of the Advisory Board of the University of Chicago Booth Graduate School of Business, and as a member of the Chicago Council on Global Affairs chairing the Global Health Policy Roundtable. Mr. Tyree earned his B.A. in psychology and forensic studies and an M.B.A. from Indiana University. - James L. Tyree，自2012年5月起担任董事会成员，自2021年7月起担任Genelux Corporation首席独立董事。Tyree先生此前曾于2014年至2021年担任董事会主席。Tyree先生是Tyree & D'Angelo Partners的退休联合创始人和管理合伙人，该公司是一家成立于2014年的私募股权投资公司。在创立Tyree & D'Angelo Partners之前，Tyree先生于2012年担任Abbott Biotech Ventures（Abbott）的执行副总裁兼总裁，该公司是雅培的子公司。在担任该职位之前，Tyree先生曾在雅培担任多个行政职务，包括执行副总裁Global Pharmaceuticals、高级副总裁Global Nutrition、公司副总裁制药和营养产品集团业务发展以及部门副总裁兼总经理，1997年至2000年，日本。Tyree先生还自2012年6月起担任生物制药公司ChemoCentryx，Inc.的董事会成员，直到该公司于2022年出售给安进，当时担任首席独立董事。Tyree先生此前曾于2012年3月至2022年11月担任医疗器械公司SonarMed，Inc.（现为美敦力 PLC的子公司）的董事会成员。Tyree先生于2016年10月至2024年4月期间担任上市制药公司Assertio Holdings, Inc.的董事会成员和薪酬委员会主席。Tyree先生此前曾担任伊利诺伊州生物技术产业组织董事会主席、芝加哥大学布斯商学院顾问委员会成员，以及主持全球健康政策圆桌会议的芝加哥全球事务委员会成员。Tyree先生获得了心理学和法医学研究学士学位，并获得了印第安纳大学的工商管理硕士学位。
- James L. Tyree,has served as a member of the Board since May 2012 and as Genelux Corporation Lead Independent Director since July 2021. Mr. Tyree previously served as Chairman of the Board from 2014 to 2021. Mr. Tyree is the retired co-founder and managing partner of Tyree & D'Angelo Partners, a private equity investment firm founded in 2014. Prior to founding Tyree & D'Angelo Partners, Mr. Tyree served as Executive Vice President and President of Abbott Biotech Ventures (Abbott), a subsidiary of Abbott Laboratories in 2012. Prior to that position, Mr. Tyree held numerous executive positions at Abbott, including Executive Vice President Global Pharmaceuticals, Senior Vice President Global Nutrition, Corporate Vice President Pharmaceutical and Nutritional Products Group Business Development and Divisional Vice President and General Manager, Japan from 1997 to 2000. Mr. Tyree also served as a member of the board of directors of ChemoCentryx, Inc., a biopharmaceutical company, since June 2012, until the company was sold to Amgen in 2022 and at that time was lead independent director. Mr. Tyree previously served as a member of the board of directors of SonarMed, Inc., a medical device company (now a subsidiary of Medtronic plc), from March 2012 to November 2022. Mr. Tyree served as a member of the board of directors and chair of the compensation committee of Assertio Holdings, Inc., a public pharmaceutical company, from October 2016 to April 2024. Mr. Tyree previously served as chairman of the board of directors of the Illinois Biotechnology Industry Organization, as a member of the Advisory Board of the University of Chicago Booth Graduate School of Business, and as a member of the Chicago Council on Global Affairs chairing the Global Health Policy Roundtable. Mr. Tyree earned his B.A. in psychology and forensic studies and an M.B.A. from Indiana University.
高管简历
中英对照 | 中文 | 英文- Thomas Zindrick
Thomas Zindrick自2014年5月起担任Genelux公司总裁、首席执行官和Genelux公司董事会成员，自2021年7月起担任Genelux公司主席。目前，他担任Aeromics，Inc的执行主席，该公司是一家临床阶段的制药公司，自2018年8月起开发用于治疗缺血性中风水肿的产品。2012年至2014年，Zindrick先生担任Amitech Therapeutic Solutions，Inc.的首席执行官。1993年至2009年，Zindrick先生在安进公司担任越来越重要的职务，包括2001年至2004年担任副总裁副总法律顾问，2008年至2009年再次担任该职务。2004年至2008年，Zindrick先生在安进公司担任首席合规官。在加入Amgen公司之前，Zindrick先生是陶氏化学公司的一名律师。Zindrick先生于2011年至2021年2月担任Amitech Therapeutic Solutions，Inc.的董事会成员，并于2014年11月至2020年3月担任DNX Biopharmaceuticals，Inc.的董事会成员。Zindrick先生在伊利诺伊大学法学院获得法学博士学位，在伊利诺斯州内珀维尔的北中央学院获得生物学学士学位。
Thomas Zindrick,has served as Genelux Corporation President, Chief Executive Officer and a member of Genelux Corporation Board since May 2014 and as Genelux Corporation Chair since July 2021. Currently, he serves as Executive Chair of Aeromics, Inc., a clinical-stage pharmaceutical company developing products for the treatment of edema in ischemic stroke, since August 2018. Mr. Zindrick served as Chief Executive Officer of Amitech Therapeutic Solutions, Inc., from March 2012 to May 2014. From 1993 to 2009, Mr. Zindrick was at Amgen Inc. ("Amgen"), a public commercial biotechnology company, where he held positions of increasing responsibility, including Vice President Associate General Counsel from 2001 to 2004 and again from 2008 to 2009. At Amgen, from 2004 to 2008, Mr. Zindrick served as Chief Compliance Officer. Prior to joining Amgen, Mr. Zindrick was an attorney at The Dow Chemical Company. Mr. Zindrick served on the board of directors of Amitech Therapeutic Solutions, Inc. from October 2011 to February 2021 and DNX Biopharmaceuticals, Inc. from November 2014 to March 2020. Mr. Zindrick received his J.D. from the University of Illinois College of Law and a B.A. in biology from North Central College in Naperville, Illinois.- Thomas Zindrick自2014年5月起担任Genelux公司总裁、首席执行官和Genelux公司董事会成员，自2021年7月起担任Genelux公司主席。目前，他担任Aeromics，Inc的执行主席，该公司是一家临床阶段的制药公司，自2018年8月起开发用于治疗缺血性中风水肿的产品。2012年至2014年，Zindrick先生担任Amitech Therapeutic Solutions，Inc.的首席执行官。1993年至2009年，Zindrick先生在安进公司担任越来越重要的职务，包括2001年至2004年担任副总裁副总法律顾问，2008年至2009年再次担任该职务。2004年至2008年，Zindrick先生在安进公司担任首席合规官。在加入Amgen公司之前，Zindrick先生是陶氏化学公司的一名律师。Zindrick先生于2011年至2021年2月担任Amitech Therapeutic Solutions，Inc.的董事会成员，并于2014年11月至2020年3月担任DNX Biopharmaceuticals，Inc.的董事会成员。Zindrick先生在伊利诺伊大学法学院获得法学博士学位，在伊利诺斯州内珀维尔的北中央学院获得生物学学士学位。
- Thomas Zindrick,has served as Genelux Corporation President, Chief Executive Officer and a member of Genelux Corporation Board since May 2014 and as Genelux Corporation Chair since July 2021. Currently, he serves as Executive Chair of Aeromics, Inc., a clinical-stage pharmaceutical company developing products for the treatment of edema in ischemic stroke, since August 2018. Mr. Zindrick served as Chief Executive Officer of Amitech Therapeutic Solutions, Inc., from March 2012 to May 2014. From 1993 to 2009, Mr. Zindrick was at Amgen Inc. ("Amgen"), a public commercial biotechnology company, where he held positions of increasing responsibility, including Vice President Associate General Counsel from 2001 to 2004 and again from 2008 to 2009. At Amgen, from 2004 to 2008, Mr. Zindrick served as Chief Compliance Officer. Prior to joining Amgen, Mr. Zindrick was an attorney at The Dow Chemical Company. Mr. Zindrick served on the board of directors of Amitech Therapeutic Solutions, Inc. from October 2011 to February 2021 and DNX Biopharmaceuticals, Inc. from November 2014 to March 2020. Mr. Zindrick received his J.D. from the University of Illinois College of Law and a B.A. in biology from North Central College in Naperville, Illinois.
- Tony Yu
Tony Yu，自2010年1月起担任Genelux公司临床试验运营部副总裁。在此之前，他曾于2008年至2010年担任Genelux公司主管临床前运营和临床前业务发展的副副总裁。从2002年到2008年，于博士受雇于Genelux公司，担任研究科学家和影像组主任。余博士在犹他大学获得生物学学士学位，在洛马林达大学获得解剖学和生物化学博士学位。
Tony Yu,has served as Genelux Corporation Senior Vice President of Clinical Development since July 2023. He previously served as Genelux Corporation Vice President of Clinical Trial Operations since January 2010. From 2008 to 2010, he served as Genelux Corporation Associate Vice President of Preclinical Research and Business Development. From 2002 to 2008, Dr. Yu was Director of the Imaging Group and Director of Tumor Diagnosis/Therapy. Dr. Yu received a B.A. in biology from the University of Utah and a Ph.D. in anatomy and biochemistry from Loma Linda University.- Tony Yu，自2010年1月起担任Genelux公司临床试验运营部副总裁。在此之前，他曾于2008年至2010年担任Genelux公司主管临床前运营和临床前业务发展的副副总裁。从2002年到2008年，于博士受雇于Genelux公司，担任研究科学家和影像组主任。余博士在犹他大学获得生物学学士学位，在洛马林达大学获得解剖学和生物化学博士学位。
- Tony Yu,has served as Genelux Corporation Senior Vice President of Clinical Development since July 2023. He previously served as Genelux Corporation Vice President of Clinical Trial Operations since January 2010. From 2008 to 2010, he served as Genelux Corporation Associate Vice President of Preclinical Research and Business Development. From 2002 to 2008, Dr. Yu was Director of the Imaging Group and Director of Tumor Diagnosis/Therapy. Dr. Yu received a B.A. in biology from the University of Utah and a Ph.D. in anatomy and biochemistry from Loma Linda University.
- Joseph Cappello
Joseph Cappello，自2012年11月起担任Genelux公司药物开发副总裁，自2018年9月起担任制造总经理。在此之前的1988年至2010年，Cappello博士担任Protein Polymer Technologies Inc.的副总裁兼首席技术官。2012年1月至9月，Cappello博士在B. Braun Medical Inc.生物试验中心担任董事兼总经理。Cappello博士在辛辛那提大学医学院获得生物化学博士学位，在加利福尼亚大学戴维斯分校获得分子和普通遗传学学士学位。
Joseph Cappello,has served as Genelux Corporation Chief Technical Officer since July 2023. He previously served as Genelux Corporation General Manager of Manufacturing since September 2018 and Genelux Corporation Vice President of Pharmaceutical Development since November 2012. From 1988 to 2010, Dr. Cappello served as the Vice President and Chief Technology Officer of Protein Polymer Technologies Inc. From January to September 2012, Dr. Cappello served as the Director and General Manager in the Biological Test Center of B. Braun Medical Inc. Dr. Cappello earned his Ph.D. in Biological Chemistry from the University of Cincinnati, College of Medicine, and his B.S. in Molecular and General Genetics from the University of California, Davis.- Joseph Cappello，自2012年11月起担任Genelux公司药物开发副总裁，自2018年9月起担任制造总经理。在此之前的1988年至2010年，Cappello博士担任Protein Polymer Technologies Inc.的副总裁兼首席技术官。2012年1月至9月，Cappello博士在B. Braun Medical Inc.生物试验中心担任董事兼总经理。Cappello博士在辛辛那提大学医学院获得生物化学博士学位，在加利福尼亚大学戴维斯分校获得分子和普通遗传学学士学位。
- Joseph Cappello,has served as Genelux Corporation Chief Technical Officer since July 2023. He previously served as Genelux Corporation General Manager of Manufacturing since September 2018 and Genelux Corporation Vice President of Pharmaceutical Development since November 2012. From 1988 to 2010, Dr. Cappello served as the Vice President and Chief Technology Officer of Protein Polymer Technologies Inc. From January to September 2012, Dr. Cappello served as the Director and General Manager in the Biological Test Center of B. Braun Medical Inc. Dr. Cappello earned his Ph.D. in Biological Chemistry from the University of Cincinnati, College of Medicine, and his B.S. in Molecular and General Genetics from the University of California, Davis.
- Ralph Smalling
自2014年起担任Genelux Corporation监管主管。此前，他曾在安进担任越来越重要的职务，包括负责监管事务和国际安全的副总裁。在他的领导下，安进在美国、欧洲、加拿大和澳大利亚获得了许多产品的上市许可、补充批准和孤儿药资格。斯莫林是谈判PDUFA II的行业团队成员之一，他起草了1997年国会通过的FDAMA立法中的几项条款。斯莫林先生在加州州立大学长滩分校获得了微生物学硕士学位，并在西方学院获得了生物学学士学位。
Ralph Smalling,has served as Genelux Corporation Head of Regulatory since July 2023. From 2005 to present, Mr. Smalling has served as Principal Consultant at Linus Consulting, LLC and has provided regulatory support to numerous companies, including Aeromics, a clinical-stage biopharmaceutical company since March 2019, Medicines Development for Global Health, a non-profit pharmaceutical organization since February 2014; and Lanier Biotherapeutics, a biotechnology company since September 2022. Mr. Smalling serves as a member of the board of directors for SymBio Pharmaceuticals, Inc., a global pharmaceutical company since April 2025. Mr. Smalling has over 40 years of experience in the biopharmaceutical industry, with expertise in all aspects of regulatory development and international safety. From February 1982 to May 2005, he served at Amgen in positions of increasing responsibility, including Vice President of Regulatory Affairs and International Safety. Under his leadership, Amgen obtained marketing authorizations, supplemental approvals and orphan drug designations in the United States, Europe, Canada and Australia for numerous products. Mr. Smalling was a member of the industry team that negotiated PDUFA II and drafted several of the provisions included in the FDAMA legislation passed by Congress in 1997. Mr. Smalling earned an M.S. in Microbiology from California State University, Long Beach, and a B.A. in Biology from Occidental College.- 自2014年起担任Genelux Corporation监管主管。此前，他曾在安进担任越来越重要的职务，包括负责监管事务和国际安全的副总裁。在他的领导下，安进在美国、欧洲、加拿大和澳大利亚获得了许多产品的上市许可、补充批准和孤儿药资格。斯莫林是谈判PDUFA II的行业团队成员之一，他起草了1997年国会通过的FDAMA立法中的几项条款。斯莫林先生在加州州立大学长滩分校获得了微生物学硕士学位，并在西方学院获得了生物学学士学位。
- Ralph Smalling,has served as Genelux Corporation Head of Regulatory since July 2023. From 2005 to present, Mr. Smalling has served as Principal Consultant at Linus Consulting, LLC and has provided regulatory support to numerous companies, including Aeromics, a clinical-stage biopharmaceutical company since March 2019, Medicines Development for Global Health, a non-profit pharmaceutical organization since February 2014; and Lanier Biotherapeutics, a biotechnology company since September 2022. Mr. Smalling serves as a member of the board of directors for SymBio Pharmaceuticals, Inc., a global pharmaceutical company since April 2025. Mr. Smalling has over 40 years of experience in the biopharmaceutical industry, with expertise in all aspects of regulatory development and international safety. From February 1982 to May 2005, he served at Amgen in positions of increasing responsibility, including Vice President of Regulatory Affairs and International Safety. Under his leadership, Amgen obtained marketing authorizations, supplemental approvals and orphan drug designations in the United States, Europe, Canada and Australia for numerous products. Mr. Smalling was a member of the industry team that negotiated PDUFA II and drafted several of the provisions included in the FDAMA legislation passed by Congress in 1997. Mr. Smalling earned an M.S. in Microbiology from California State University, Long Beach, and a B.A. in Biology from Occidental College.
- Matthew Pulisic
Matthew Pulisic，自2025年1月起担任Genelux Corporation首席财务官。Pulisic先生最近于2020年8月至2025年1月在上市的RNAi技术公司箭头制药担任财务副总裁。他在塑造公司的财务方向、领导规划和分析、建立商业制造设施以及推动运营改进以支持公司从临床阶段演变为商业前组织方面发挥了关键作用。在此之前，Pulisic先生曾于2019年8月至2020年8月在三星电子有限公司的独立子公司HARMAN International担任全球产品开发、研发、全球营销和采购的财务主管。他于2006年4月在安进开始了他的职业生涯，担任研究助理，并过渡到财务部门，在那里他担任的职位责任越来越大，包括商业财务、公司财务、财务、安进全球财务总监和资本财务主管，时间跨度从2007年到2019年。普利西奇先生在加州路德大学获得金融硕士学位，在加州大学圣克鲁斯分校获得生物化学和分子生物学学士学位。
Matthew Pulisic,has served as Genelux Corporation Chief Financial Officer since January 2025. Mr. Pulisic most recently served as Vice President of Finance at Arrowhead Pharmaceuticals, a publicly traded RNAi technology company, from August 2020 to January 2025. He played a key role in shaping the company's financial direction, leading planning and analysis, establishing a commercial manufacturing facility, and driving operational improvements to support the company's evolution from a clinical-stage to a pre-commercial organization. Prior to that, Mr. Pulisic served as Head of Finance for Global Product Development, R&D, Global Marketing & Sourcing at HARMAN International, a standalone subsidiary of Samsung Electronics Co. Ltd., from August 2019 to August 2020. He began his career at Amgen in April 2006 as a Research Associate and transitioned into finance where he held positions of increasing responsibility, including Commercial Finance, Corporate Finance, Treasury, Finance Director of Amgen Worldwide and Head of Capital Finance, spanning from 2007 to 2019. Mr. Pulisic received his M.B.A. in finance from the California Lutheran University and a B.S. in Biochemistry and Molecular Biology from the University of California, Santa Cruz.- Matthew Pulisic，自2025年1月起担任Genelux Corporation首席财务官。Pulisic先生最近于2020年8月至2025年1月在上市的RNAi技术公司箭头制药担任财务副总裁。他在塑造公司的财务方向、领导规划和分析、建立商业制造设施以及推动运营改进以支持公司从临床阶段演变为商业前组织方面发挥了关键作用。在此之前，Pulisic先生曾于2019年8月至2020年8月在三星电子有限公司的独立子公司HARMAN International担任全球产品开发、研发、全球营销和采购的财务主管。他于2006年4月在安进开始了他的职业生涯，担任研究助理，并过渡到财务部门，在那里他担任的职位责任越来越大，包括商业财务、公司财务、财务、安进全球财务总监和资本财务主管，时间跨度从2007年到2019年。普利西奇先生在加州路德大学获得金融硕士学位，在加州大学圣克鲁斯分校获得生物化学和分子生物学学士学位。
- Matthew Pulisic,has served as Genelux Corporation Chief Financial Officer since January 2025. Mr. Pulisic most recently served as Vice President of Finance at Arrowhead Pharmaceuticals, a publicly traded RNAi technology company, from August 2020 to January 2025. He played a key role in shaping the company's financial direction, leading planning and analysis, establishing a commercial manufacturing facility, and driving operational improvements to support the company's evolution from a clinical-stage to a pre-commercial organization. Prior to that, Mr. Pulisic served as Head of Finance for Global Product Development, R&D, Global Marketing & Sourcing at HARMAN International, a standalone subsidiary of Samsung Electronics Co. Ltd., from August 2019 to August 2020. He began his career at Amgen in April 2006 as a Research Associate and transitioned into finance where he held positions of increasing responsibility, including Commercial Finance, Corporate Finance, Treasury, Finance Director of Amgen Worldwide and Head of Capital Finance, spanning from 2007 to 2019. Mr. Pulisic received his M.B.A. in finance from the California Lutheran University and a B.S. in Biochemistry and Molecular Biology from the University of California, Santa Cruz.
- Eric Groen
Eric Groen，自2025年7月起担任Genelux Corporation总法律顾问、公司秘书、首席合规官和业务发展主管。在加入Genelux Corporation之前，Groen先生于2021年7月至2025年5月期间担任临床阶段的上市生物技术公司Rani Therapeutics Holdings, Inc.的总法律顾问。Groen先生还于2022年2月至2023年5月在Rani Therapeutics领导业务发展。在此之前，从2001年9月到2021年7月，Groen先生在全球生物技术公司安进公司担任过各种国内和国际角色，职责不断增加，包括领导负责业务发展交易、运营和制造以及临床试验的法律团队。他还曾担任安进在加拿大、拉丁美洲、中东和非洲的商业业务的区域总法律顾问。从1999年1月到2001年8月，Groen先生在HealthNet担任公司法律顾问，HealthNet是一家管理式医疗和其他医疗保健实体的公共控股公司。在此之前，Groen先生是TroyGould律师事务所的合伙人。Groen先生获得了加州大学圣巴巴拉分校政治学学士学位和哈佛大学法学院法学博士学位。
Eric Groen,has served as Genelux Corporation General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development since July 2025. Prior to joining Genelux Corporation , Mr. Groen served as general counsel for Rani Therapeutics Holdings, Inc., a clinical-stage, public biotechnology company, from July 2021 to May 2025. Mr. Groen also led business development at Rani Therapeutics from February 2022 to May 2023. Previously, from September 2001 to July 2021, Mr. Groen served in various domestic and international roles of increasing responsibility at Amgen Inc., a global biotechnology company, including leading the legal teams responsible for business development transactions, operations and manufacturing, and clinical trials. He also served as regional general counsel to Amgen's commercial business in Canada, Latin America, Middle East and Africa. From January 1999 to August 2001, Mr. Groen was corporate counsel at HealthNet, a public holding company of managed care and other healthcare entities. Prior to that, Mr. Groen was an associate at the law firm of TroyGould. Mr. Groen earned a B.A. in Political Science from the University of California, Santa Barbara and a J.D. from Harvard Law School.- Eric Groen，自2025年7月起担任Genelux Corporation总法律顾问、公司秘书、首席合规官和业务发展主管。在加入Genelux Corporation之前，Groen先生于2021年7月至2025年5月期间担任临床阶段的上市生物技术公司Rani Therapeutics Holdings, Inc.的总法律顾问。Groen先生还于2022年2月至2023年5月在Rani Therapeutics领导业务发展。在此之前，从2001年9月到2021年7月，Groen先生在全球生物技术公司安进公司担任过各种国内和国际角色，职责不断增加，包括领导负责业务发展交易、运营和制造以及临床试验的法律团队。他还曾担任安进在加拿大、拉丁美洲、中东和非洲的商业业务的区域总法律顾问。从1999年1月到2001年8月，Groen先生在HealthNet担任公司法律顾问，HealthNet是一家管理式医疗和其他医疗保健实体的公共控股公司。在此之前，Groen先生是TroyGould律师事务所的合伙人。Groen先生获得了加州大学圣巴巴拉分校政治学学士学位和哈佛大学法学院法学博士学位。
- Eric Groen,has served as Genelux Corporation General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development since July 2025. Prior to joining Genelux Corporation , Mr. Groen served as general counsel for Rani Therapeutics Holdings, Inc., a clinical-stage, public biotechnology company, from July 2021 to May 2025. Mr. Groen also led business development at Rani Therapeutics from February 2022 to May 2023. Previously, from September 2001 to July 2021, Mr. Groen served in various domestic and international roles of increasing responsibility at Amgen Inc., a global biotechnology company, including leading the legal teams responsible for business development transactions, operations and manufacturing, and clinical trials. He also served as regional general counsel to Amgen's commercial business in Canada, Latin America, Middle East and Africa. From January 1999 to August 2001, Mr. Groen was corporate counsel at HealthNet, a public holding company of managed care and other healthcare entities. Prior to that, Mr. Groen was an associate at the law firm of TroyGould. Mr. Groen earned a B.A. in Political Science from the University of California, Santa Barbara and a J.D. from Harvard Law School.
- Jason Litten
Jason Litten，最近自2022年7月起担任Chimeric Therapeutics，Ltd.的首席医疗官。Litten博士是临床肿瘤学专家，拥有开发多种治疗模式的经验。Litten博士特别开发了一些首批CAR-T、TCR和NK细胞临床项目，并领导了众多治疗性单克隆抗体和口服癌症药物的临床和临床前开发。从2019年8月到2022年3月，Litten博士在Artiva Biotherapeutics，Inc.担任首席医疗官，在那里他构建并领导了Artiva的临床和监管职能。在Artiva任职期间，Litten博士为启动两个临床NK细胞治疗项目做出了贡献，筹集了超过2亿美元的私人融资，并建立了两个基础性的企业合作伙伴关系。2019年1月至2019年6月，Litten博士在Optera Therapeutics Corp.担任首席医疗官。2016年9月至2018年5月，Litten博士在Juno Therapeutics, Inc.担任临床开发副总裁，负责监督实体瘤项目。在Juno之前，他在TERM0担任临床开发副总裁。Clovis Oncology, Inc. Litten博士在TERM0 Amgen Inc.开始了他的肿瘤临床开发行业生涯。安进公司 Litten博士拥有康奈尔大学财经学士学位和埃默里大学医学博士学位。医学院毕业后，他在迈阿密大学完成了普通儿科的住院治疗，并在达拉斯的UT西南医学中心完成了儿科血液学和肿瘤学的临床研究金。
Jason Litten,most recently served as the Chief Medical Officer of Chimeric Therapeutics, Ltd. since July 2022. Dr. Litten is an expert in clinical oncology with experience developing numerous therapeutics modalities. Dr. Litten notably developed some of the first CAR-T, TCR and NK cell clinical programs, as well as leading the clinical and preclinical development of numerous therapeutic monoclonal antibodies and orally available cancer medicines. From August 2019 to March 2022, Dr. Litten served as the Chief Medical Officer at Artiva Biotherapeutics, Inc. where he built and led Artiva's clinical and regulatory functions. During his time at Artiva, Dr. Litten contributed to launching two clinical NK cell therapy programs, raising over $200 million in private financing and establishing two foundational corporate partnerships. From January 2019 to June 2019, Dr. Litten served as Chief Medical Officer at Optera Therapeutics Corp., and from September 2016 to May 2018, Dr. Litten was the Vice President of Clinical Development overseeing solid tumor programs at Juno Therapeutics, Inc. Before Juno, he was Vice President of Clinical Development at Clovis Oncology, Inc. Dr. Litten started his industry career in Oncology Clinical Development at Amgen Inc. Dr. Litten holds a B.S. in Finance and Economics from Cornell University and M.D. from Emory University. After medical school, he completed a Residency in General Pediatrics at University of Miami and a Clinical Fellowship in Pediatric Hematology & Oncology at UT Southwestern Medical Center at Dallas.- Jason Litten，最近自2022年7月起担任Chimeric Therapeutics，Ltd.的首席医疗官。Litten博士是临床肿瘤学专家，拥有开发多种治疗模式的经验。Litten博士特别开发了一些首批CAR-T、TCR和NK细胞临床项目，并领导了众多治疗性单克隆抗体和口服癌症药物的临床和临床前开发。从2019年8月到2022年3月，Litten博士在Artiva Biotherapeutics，Inc.担任首席医疗官，在那里他构建并领导了Artiva的临床和监管职能。在Artiva任职期间，Litten博士为启动两个临床NK细胞治疗项目做出了贡献，筹集了超过2亿美元的私人融资，并建立了两个基础性的企业合作伙伴关系。2019年1月至2019年6月，Litten博士在Optera Therapeutics Corp.担任首席医疗官。2016年9月至2018年5月，Litten博士在Juno Therapeutics, Inc.担任临床开发副总裁，负责监督实体瘤项目。在Juno之前，他在TERM0担任临床开发副总裁。Clovis Oncology, Inc. Litten博士在TERM0 Amgen Inc.开始了他的肿瘤临床开发行业生涯。安进公司 Litten博士拥有康奈尔大学财经学士学位和埃默里大学医学博士学位。医学院毕业后，他在迈阿密大学完成了普通儿科的住院治疗，并在达拉斯的UT西南医学中心完成了儿科血液学和肿瘤学的临床研究金。
- Jason Litten,most recently served as the Chief Medical Officer of Chimeric Therapeutics, Ltd. since July 2022. Dr. Litten is an expert in clinical oncology with experience developing numerous therapeutics modalities. Dr. Litten notably developed some of the first CAR-T, TCR and NK cell clinical programs, as well as leading the clinical and preclinical development of numerous therapeutic monoclonal antibodies and orally available cancer medicines. From August 2019 to March 2022, Dr. Litten served as the Chief Medical Officer at Artiva Biotherapeutics, Inc. where he built and led Artiva's clinical and regulatory functions. During his time at Artiva, Dr. Litten contributed to launching two clinical NK cell therapy programs, raising over $200 million in private financing and establishing two foundational corporate partnerships. From January 2019 to June 2019, Dr. Litten served as Chief Medical Officer at Optera Therapeutics Corp., and from September 2016 to May 2018, Dr. Litten was the Vice President of Clinical Development overseeing solid tumor programs at Juno Therapeutics, Inc. Before Juno, he was Vice President of Clinical Development at Clovis Oncology, Inc. Dr. Litten started his industry career in Oncology Clinical Development at Amgen Inc. Dr. Litten holds a B.S. in Finance and Economics from Cornell University and M.D. from Emory University. After medical school, he completed a Residency in General Pediatrics at University of Miami and a Clinical Fellowship in Pediatric Hematology & Oncology at UT Southwestern Medical Center at Dallas.